Dupilumab Provides Clinically Meaningful Responses in Children Aged 6–11 Years with Severe Atopic Dermatitis: Post Hoc Analysis Results from a Phase III Trial

BACKGROUND: Children with severe atopic dermatitis (AD) have a multidimensional disease burden. OBJECTIVE: Here we assess the clinically meaningful improvements in AD signs, symptoms, and quality of life (QoL) in children aged 6–11 years with severe AD treated with dupilumab compared with placebo. M...

Descripción completa

Detalles Bibliográficos
Autores principales: Siegfried, Elaine C., Cork, Michael J., Katoh, Norito, Zhang, Haixin, Chuang, Chien-Chia, Thomas, Ryan B., Rossi, Ana B., Cyr, Sonya L., Zhang, Annie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10460374/
https://www.ncbi.nlm.nih.gov/pubmed/37300760
http://dx.doi.org/10.1007/s40257-023-00791-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10460374/
https://www.ncbi.nlm.nih.gov/pubmed/37300760
http://dx.doi.org/10.1007/s40257-023-00791-7

Ejemplares similares